Response to Reviewer 4 Comments In general, the manuscript is well written and provides novel and interesting data illustrating the possibility to enhance the efficacy of sorafenib in the therapy of hepatocellular carcinoma (HCC).
Finally, adding to all the above questions, I found a very weak Discussion section which must be extended. Moreover, in the Discussion section, the authors concluded that “TTFields display efficacy for treatment of HCC in vitro and in vivo, with an optimal frequency of 150 kHz”. This is not a correct statement. While for in vitro data, the authors have data, for in vivo they used only one frequency of 150 Hz. At least one different dose should have been studied for comparison since this is a completely different tumor environment than the in vitro one.